6533b822fe1ef96bd127cef6
RESEARCH PRODUCT
Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions.
Gerd DannhardtMichaela Jansensubject
PsychosisGlycinePainPharmacologyNeurotransmissionInhibitory postsynaptic potentialReceptors N-Methyl-D-AspartateGlycine bindingMemantineDrug DiscoverymedicineAnimalsHumansReceptorGlycine receptorPharmacologychemistry.chemical_classificationBinding SitesEpilepsyOrganic ChemistryGlutamate receptorGeneral Medicinemedicine.diseaseAmino acidStrokeNeuroprotective AgentsBiochemistrychemistryGlycineSchizophreniaNMDA receptorAnticonvulsantsDementiaExcitatory Amino Acid Antagonistsdescription
For decades neuroreceptor research has focused on the development of NMDA glycine-site antagonists, after Johnson and Ascher found out in 1987 about the co-agonistic character of this achiral amino acid at the NMDA receptor. Contrary to the inhibitory glycine receptor (glycine(A)) the glycine binding site on the NMDA receptor (glycine(B)) is strychnine-insensitive. A great diversity of diseases showing a disturbed glutamate neurotransmission have been linked to the NMDA receptor. Glycine site antagonists have been investigated for acute diseases like stroke and head trauma as well as chronic ones like dementia and chronic pain.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2003-07-01 | European journal of medicinal chemistry |